Malignant ascites is the most common cause of death from ovarian cancer, and SPARC normalizes malignant ascites in the ovarian cancer microenvironment and improves inflammation through downregulating the VEGF–integrin–MMP axis. Here, VEGFA is linked to ovarian carcinoma.